A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
13
07
2023
medline:
25
9
2023
pubmed:
18
8
2023
entrez:
18
8
2023
Statut:
ppublish
Résumé
With the rising importance of precision oncology in biliary tract cancer (BTC), the aim of this retrospective single-center analysis was to describe the clinical and molecular characteristics of patients with BTC who underwent comprehensive genomic profiling (CGP) and were discussed in the CCCMunich In this single-center observational study, we included BTC patients with intrahepatic cholangiocarcinoma (iCCA), extrahepatic CCA (eCCA), and gallbladder cancer (GB), who had been discussed in the institutional MTB from May 29, 2017, to July 25, 2022. Patients were followed up until 31 January 2023. Data were retrospectively collected by review of medical charts, and MTB recommendation. In total, 153 cases were registered to the MTB with a median follow-up of 15 months. Testing was successful in 81.7% of the patients. CGP detected targetable alterations in 35.3% of our BTC patients (most commonly ARID1A/ERBB2/IDH1/PIK3CA/BRAF-mutations and FGFR2-fusions). Recommendations for molecularly guided therapy were given in 46.4%. Of those, treatment implementation of targeted therapy followed in 19.4%. In patients receiving the recommended treatment, response rate was 57% and median overall survival was 19 months (vs 8 months in the untreated cohort). The progression-free survival ratio of 1.45 suggest a clinical benefit of molecularly guided treatment. In line with previous work, our series demonstrates feasibility and clinical utility of comprehensive genomic profiling in BTC patients. With the growing number of targeted agents with clinical activity in BTC, CGP should become standard of care in the management of this group of patients.
Sections du résumé
BACKGROUND AND OBJECTIVE
With the rising importance of precision oncology in biliary tract cancer (BTC), the aim of this retrospective single-center analysis was to describe the clinical and molecular characteristics of patients with BTC who underwent comprehensive genomic profiling (CGP) and were discussed in the CCCMunich
PATIENTS AND METHODS
In this single-center observational study, we included BTC patients with intrahepatic cholangiocarcinoma (iCCA), extrahepatic CCA (eCCA), and gallbladder cancer (GB), who had been discussed in the institutional MTB from May 29, 2017, to July 25, 2022. Patients were followed up until 31 January 2023. Data were retrospectively collected by review of medical charts, and MTB recommendation.
RESULTS
In total, 153 cases were registered to the MTB with a median follow-up of 15 months. Testing was successful in 81.7% of the patients. CGP detected targetable alterations in 35.3% of our BTC patients (most commonly ARID1A/ERBB2/IDH1/PIK3CA/BRAF-mutations and FGFR2-fusions). Recommendations for molecularly guided therapy were given in 46.4%. Of those, treatment implementation of targeted therapy followed in 19.4%. In patients receiving the recommended treatment, response rate was 57% and median overall survival was 19 months (vs 8 months in the untreated cohort). The progression-free survival ratio of 1.45 suggest a clinical benefit of molecularly guided treatment.
CONCLUSIONS
In line with previous work, our series demonstrates feasibility and clinical utility of comprehensive genomic profiling in BTC patients. With the growing number of targeted agents with clinical activity in BTC, CGP should become standard of care in the management of this group of patients.
Identifiants
pubmed: 37594677
doi: 10.1007/s11523-023-00985-3
pii: 10.1007/s11523-023-00985-3
pmc: PMC10517894
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
767-776Informations de copyright
© 2023. The Author(s).
Références
Ann Oncol. 2019 May 1;30(5):661-663
pubmed: 30865225
J Clin Oncol. 2022 Aug 20;40(24):2716-2734
pubmed: 35839428
Clin Cancer Res. 2022 Apr 14;28(8):1662-1671
pubmed: 35042699
Br J Cancer. 2022 Nov;127(9):1701-1708
pubmed: 35986087
Ann Oncol. 2023 Feb;34(2):127-140
pubmed: 36372281
Trends Cancer. 2018 Feb;4(2):101-109
pubmed: 29458960
J Gastrointest Oncol. 2016 Oct;7(5):797-803
pubmed: 27747093
Lancet Oncol. 2021 Sep;22(9):1290-1300
pubmed: 34339623
JAMA Oncol. 2021 Nov 01;7(11):1669-1677
pubmed: 34554208
Clin Cancer Res. 1998 May;4(5):1079-86
pubmed: 9607564
Trends Cancer. 2020 Sep;6(9):738-744
pubmed: 32517959
Cancer Discov. 2021 Feb;11(2):326-339
pubmed: 33218975
Am J Clin Pathol. 2020 Apr 15;153(5):598-604
pubmed: 31844887
Lancet Oncol. 2023 Jul;24(7):772-782
pubmed: 37276871
Clin J Gastroenterol. 2021 Oct;14(5):1459-1463
pubmed: 34085164
ESMO Open. 2019 Nov 13;4(6):e000583
pubmed: 31798980
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Cancer Res Clin Oncol. 2023 May;149(5):1905-1915
pubmed: 35796778
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
N Engl J Med. 2023 Jan 19;388(3):228-239
pubmed: 36652354
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Ann Oncol. 2021 Sep;32(9):1111-1126
pubmed: 33932504
JCO Precis Oncol. 2021 Jul 09;5:
pubmed: 34632252
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
J Hepatol. 2022 May;76(5):1109-1121
pubmed: 35167909